Pacira | PCRX - Ebitda


Pacira reported $50.45M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Astellas Pharma JPY 182.02B 53.22B Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 8.99B 721M Jun/2026
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 50.45M 1.78M Sep/2026
Perrigo USD 156.6M 83M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
Teva Pharmaceutical Industries USD 1.5B 1.02B Sep/2026
Xeris Pharmaceuticals USD -20.94M 33.27M Jun/2026
Zoetis USD 1.07B 21M Sep/2026